Vera Therapeutics is expected to report a Q2 2026 net loss of $1.60 per share on revenue of $1.28 million, with its current stock price of $35.45 trading significantly below the consensus analyst price target of $84.58.
The primary focus for investors is the commercial launch progress and market access strategy for Trutakna (atacicept) following its recent FDA accelerated approval in July 2026 for IgA nephropathy.
Management commentary regarding the build-out of the specialty sales force and initial physician uptake will be critical to assessing the drug's early trajectory. Additionally, the market remains attentive to the ongoing ORIGIN Phase 3 trial, as long-term eGFR data is required to support a transition toward full regulatory approval.